A European founder targeting the US market shouldn't dismiss European VCs. You might be the top priority in a European firm's portfolio, receiving more attention and support than you would as a lower-priority deal for a top-tier, oversubscribed Silicon Valley firm.

In a major cultural shift, over 40% of students at Japan's top University of Tokyo now want to work at or found a startup. This reverses a decades-long tradition of seeking security at established firms, signaling a massive talent pipeline shift towards the venture ecosystem.

A VC advises Korean entrepreneurs to abandon gradual US entry strategies. The effective model is to "parachute" in—relocating solo to a hub like Boston and immersing oneself in the network. This radical, face-time-centric approach is deemed essential for building the momentum needed for US investment and partnerships.

Despite potential language or tax hurdles, Japan's high quality of life—including safety, public transport, and cuisine—is a powerful magnet for top international talent. Startups find it's a significant competitive advantage, making it easier to recruit globally than many expect.

To win highly sought-after deals, growth investors must build relationships years in advance. This involves providing tangible help with hiring, customer introductions, and strategic advice, effectively acting as an investor long before deploying capital.

The CEO of Korean startup Apollon, who moved his family to Cambridge, argues that sending a representative is insufficient for US expansion. He advises that the CEO must be physically present "on the ground" to build trust, navigate the ecosystem, and demonstrate commitment—a crucial lesson for any international startup targeting the US.

Don't expect the parent company's sales force to sell your nascent product. Their focus on core business means they will ignore emerging tech. An internal incubator must have its own dedicated go-to-market team to find new personas and develop sales plays before a handoff.

Japan's biotech ecosystem is evolving with a new, successful model for creating cross-border companies. US venture firms are partnering with Japanese academia, combining American management expertise and capital with Japan's strong science and cost-effective R&D to build globally competitive biotechs from their inception.

European firm Permira successfully entered the US not by just opening an office, but by relocating its top talent, empowering local decision-making, and accepting years of minimal activity to build relationships and market knowledge before scaling.